Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025 ROCKVILLE, Md. and

Ascentage Pharma to Present Data from Two Clinical

Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025

ROCKVILLE, Md. and SUZHOU, China, November

3, 2025 - Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical

company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs

in cancer, announced that the latest results from two clinical studies of its novel drug, lisaftoclax (APG-2575), have been selected for

presentations, including an oral report, at the 67th American Society of Hematology (ASH) Annual Meeting. This is the fourth consecutive

year in which clinical results on lisaftoclax have been selected by the ASH Annual Meeting. This year, data from multiple clinical and

preclinical studies on three of the company's investigational drug candidates (lisaftoclax, olverembatinib, and APG-5918) have been

selected for presentations at the ASH Annual Meeting.

Developed by Ascentage Pharma, lisaftoclax is

an orally available Bcl-2 inhibitor. Early data from the studies have demonstrated effects on hematologic malignancies and solid tumors.

Lisaftoclax is being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult

patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy

including Bruton's tyrosine kinase (BTK) inhibitors. At this year's ASH Annual Meeting, Ascentage Pharma will present an oral

report featuring the latest results from a registrational Phase II study of lisaftoclax monotherapy in patients with relapsed/refractory

(R/R) CLL/SLL. Moreover, Ascentage Pharma will present a poster featuring the latest data of lisaftoclax in combination with azacitidine

(AZA) in patients with newly diagnosed (ND) or prior venetoclax-exposed myeloid malignancies.

The ASH Annual Meeting is one of the largest gatherings

of the international hematology community, aggregating the latest scientific research on the pathogenesis and clinical treatment of hematologic

diseases. The 67th ASH Annual Meeting will take place on December 6-9, 2025, local time, both online and in-person in Orlando, Florida.

Dr. Yifan Zhai, Chief Medical Officer of Ascentage

Pharma, said, "Lisaftoclax has demonstrated efficacy and manageable safety profiles across numerous studies to-date. Lisaftoclax

is currently being evaluated in four global registrational Phase III studies. At ASH 2025, the latest clinical data supporting lisaftoclax

were once again selected for presentations, including an oral report, underscoring the drug's therapeutic potential in hematologic

diseases. We are pleased that multiple studies of our key drug candidates have been selected for presentation at the ASH Annual Meeting,

demonstrating Ascentage Pharma's robust capabilities in global innovation and clinical development. We are eager to share more detailed

results during the conference and will continue to accelerate our clinical development programs in order to bring more treatment options

to patients as soon as possible."

An overview of presentations featuring Ascentage

Pharma's drug candidates at ASH 2025:

Study abstracts on lisaftoclax selected for presentations

at the 2025 ASH Annual Meeting are as follows: (for details on the abstracts featuring olverembatinib, please refer to a separate press

release published at the same time)

Results of a registrational phase 2 study of

lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

(CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Format: Oral Presentation

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological:

Treatment of CLL in Relapse and in Richter Transformation

Time: Saturday, December 6, 2025; 10:15 AM - 10:30 AM EST

First Author: Prof. Keshu Zhou, The Affiliated Cancer Hospital

of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

Presenter: Prof. Keshu Zhou, The Affiliated Cancer Hospital

of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

This is a pivotal registrational Phase II study (NCT05147467) in patients

with CLL/SLL, with the objective response rate (ORR) as its primary endpoint. Patients in this study were refractory to, relapsed on,

or intolerant of both BTK inhibitors and immunochemotherapy; or failed prior BTK inhibitors and were ineligible for immunochemotherapy.

Results: As of July 25, 2025, among 72 evaluable patients with R/R CLL/SLL, the ORR as confirmed by the independent review

committee (IRC) was 62.5%, the median

progression-free survival (mPFS) was 23.89 months (with a median follow-up of 22.01 months). Among high-risk patients (those with

adverse prognostic genotypes such as del(17p)/TP53 mutation, chromosomal complex karyotype, and unmutated IGHV), the

treatment showed clinically meaningful deep responses. 21.8% of patients achieved minimal residual disease (MRD) negativity in

peripheral blood. In the 11 evaluable patients with bone marrow MRD, 6 achieved MRD-negativity.

Safety Results: Lisaftoclax demonstrated a manageable safety

profile in BTKi-pretreated patients. Frequent grade 3 treatment-related adverse events were hematologic toxicities that included decreased

neutrophil, decreased platelet count, and anemia. No tumor-lysis syndrome (TLS) was reported and no treatment-related deaths occurred

Conclusion: Lisaftoclax monotherapy demonstrated significant

and durable clinical efficacy and a manageable safety profile in patients with heavily-pretreated BTK-refractory R/R CLL/SLL, underscoring

its utility as a potential new treatment option.

Poster Presentation:

Results of the APG2575AU101 study of lisaftoclax

(APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax-exposed myeloid malignancies

Format: Poster Presentation

Session: 616. Acute Myeloid Leukemias: Investigational Drug

and Cellular Therapies: Poster I

Time: Saturday, December 6, 2025; 5:30 PM - 7:30 PM EST

First Author: Dr. Tapan Kadia, Department of Leukemia, The University

of Texas MD Anderson Cancer Center

Presenter: Dr. Tapan Kadia, Department of Leukemia, The University

of Texas MD Anderson Cancer Center

Efficacy Results as of July 1, 2025:

Safety Results: No dose-limiting toxicities (DLTs) were reported

in part one for dose-escalation or part two for dose-expansion. Common grade 3 treatment-emergent adverse events (TEAEs) included

neutropenia (41.7%), febrile neutropenia (35.0%), thrombocytopenia (26.2%), anemia (17.5%).

Conclusion: These preliminary clinical data show that the combination

regimen of lisaftoclax plus AZA holds promise in overcoming venetoclax resistance, therefore potentially offering a new treatment option

to patients with AML/HR MDS.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ("Ascentage

Pharma" or the "Company") is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery,

development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a

rich pipeline of innovative drug products and candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such

as Bcl-2 and MDM2-p53, as well as next-generation kinase inhibitors.

The lead asset, olverembatinib, is the first novel third-generation

BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated

phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. All indications are

covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational

Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for patients with newly diagnosed

Ph+ ALL and SDH-deficient GIST patients.

second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax is

being commercialized in China following National Medical Products Administration (NMPA) approval for the treatment of adult patients with

chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including

Bruton's tyrosine kinase (BTK) inhibitors. The Company is currently

conducting four global registrational Phase III trials: the FDA-cleared GLORA study of lisaftoclax in combination with BTK inhibitors

in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in

patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with acute myeloid leukemia (

AML); and the GLORA-4 study in patients with newly diagnosed higher-risk myelodysplastic syndrome (HR MDS), a study that was simultaneously

cleared by the US FDA, the EMA of the EU, and China CDE.